Abstract
Probiotics are live microorganisms which when administered in adequate amounts, may confer a health benefit on the host. Stimulation and regulation of immune system is among well documented benefits claimed for probiotics. Both innate and adaptive immune system can be regulated by these microorganisms. Effects of probiotics on immune system are significantly dependent on the strain, dosage and the investigated condition. In this article the mechanisms through which probiotics may regulate immune system were reviewed. These mechanisms are consist of blockage of adhesion sites for pathogenic bacteria, competition for nutrients, production of inhibitory compounds, degradation of the toxin receptors in the mucosa membrane, activation of phagocytic and natural killer cells as well as regulation of cellular and humoral immunity. Also the immune-related diseases including immune deficiency (Acquired immunodeficiency syndrome) and hypersensitivity (allergy, inflammatory bowel disease, diabetes mellitus type 1 and rheumatoid arthritis) were discussed
References
Savage DC. Factors involved in colonization of the gut epithelial surface. American Journal of Clinical Nutrition 1978; 31(10): 131-135.
Water JV, Naiyanetr P. Yogurt and Immunity, The Health Benefits of Fermented Milk Products That Contain Lactic Acid Bacteria. Handbook of Fermented Functional Foods, (Farnworth ER, ed.^eds.), CRC Press, London 2003; pp. 130-155.
Homayouni A. Letter to the editor. Food Chemistry 2009; 114: 1073. http://dx.doi.org/10.1016/j.foodchem.2008.10.012
Homayouni A, Akbarzadeh F, Vaghef Mehrbani E. Which are more important: Prebiotics or probiotics? Journal of Nutrition 2012; 28: 1196-1197. http://dx.doi.org/10.1016/j.nut.2012.03.017
Homayouni A, Azizi A, Ehsani MR, Yarmand MS, Razavi SH. Effect of microencapsulation and resistant starch on the probiotic survival and sensory properties of synbiotic ice cream. Food Chemistry 2012; 111: 50-55. http://dx.doi.org/10.1016/j.foodchem.2008.03.036
Gill HS, Grover S, Batish VK, Gill P. Immunological effects of probiotics and their significance to human health. Prebiotics and probiotics science and technology, (Charalampopoulos D, Rastall RA, ed. eds.), pp. Springer, Berlin 2009; 901-948. http://dx.doi.org/10.1007/978-0-387-79058-9_23
Haddad PS, Azar GA, Groom S, Boivin M. Natural health products, modulation of immune function and prevention of chronic diseases. Evidence-Based Complementary and Alternative Medicine 2005; 2: 513-520. http://dx.doi.org/10.1093/ecam/neh125
Cebra JJ. Influences of microbiota on intestinal immune system development. American Journal of Clinical Nutrition 1999; 69: 1046-1051.
Sepkowitz KA. AIDS-the first 20 years. The New England Journal of Medicine 2001; 344: 1764-1772. http://dx.doi.org/10.1056/NEJM200106073442306
Piatak MJ, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-1754. http://dx.doi.org/10.1126/science.8096089
Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proceedings of the National Academy of Sciences 1997; 94: 254-258. http://dx.doi.org/10.1073/pnas.94.1.254
Trois L, Cardoso EM, Miura E. Use of Probiotics in HIV-infected Children: A Randomized Double-blind Controlled Study. Journal of Tropical Pediatrics 2007; 54: 19-24. http://dx.doi.org/10.1093/tropej/fmm066
Cunningham-Rundles S, Ahrne S, Bengmark S, et al. Probio-tics and Immune Response. Gastroenterology 2000; 95: 22-25.
Irvine SL, Hummelen R, Hekmat S. Probiotic yogurt consumption may improve gastrointestinal symptoms, productivity, and nutritional intake of people living with human immunodeficiency virus in Mwanza, Tanzania. Nutrition Research 2011; 31: 875-881. http://dx.doi.org/10.1016/j.nutres.2011.10.005
Anukam KC, Osazuwa EO, Osadolor HB, Bruce AW, Reid G. Yogurt Containing Probiotic Lactobacillus rhamnosus GR-1and L. reuteri RC-14 Helps Resolve Moderate Diarrhea and Increases CD4 Count in HIV/AIDS Patients. Journal of Clinical Gastroenterology 2008; 42: 239-243.
Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhea and inflammatory bowel diseases. Journal Gastroenterol Hepatol 2000; 15: 489-493. http://dx.doi.org/10.1046/j.1440-1746.2000.02162.x
Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Digestive Diseases and Sciences 2000; 45: 1462-1464. http://dx.doi.org/10.1023/A:1005588911207
Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomized controlled trial with Lactobacillus GG. Inflammation and Inflammatory Bowel Disease 2002; 51: 405-409. http://dx.doi.org/10.1136/gut.51.3.405
Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of Pouchitis Onset With Probiotic Therapy: A Double-Blind, Placebo-Controlled Trial. The American Gastroenterological Association 2003; 124: 1202-1209. http://dx.doi.org/10.1016/s0016-5085(03)00171-9
Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Alimentary Pharmacology & Therapeutics 2003; 17: 509-515. http://dx.doi.org/10.1046/j.1365-2036.2003.01465.x
Gosselink MP, Schouten WR, van Lieshout LMC, Hop WCJ, Laman JD, Embden JGHR. Delay of the First Onset of Pouchitis by Oral Intake of the probiotic strain Lactobacillus rhamnosus GG. Diseases of the Colon & Rectum 2004; 47: 876-884. http://dx.doi.org/10.1007/s10350-004-0525-z
Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. International Medical Journal of Experimental and Clinical Research 2004; 10: 126-131.
Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Inflammatory Bowel Disease 2004; 53: 108-114. http://dx.doi.org/10.1136/gut.53.1.108
Kruis W, Fric? P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623. http://dx.doi.org/10.1136/gut.2003.037747
Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof J, A, Rath HC. Lactobacillus GG in inducing and maintaining re-mission of Crohn's disease. BMC Gastroenterology 2004; 4.
Bousvaros A, Guandalini S, Baldassano RN, et al. A Randomized, Double-blind Trial of Lactobacillus GG Versus Placebo in Addition to Standard Maintenance Therapy for Children with Crohn’s Disease. Inflammatory Bowel Disease 2005; 11: 833-839. http://dx.doi.org/10.1097/01.MIB.0000175905.00212.2c
Zocco MA, Zileri dal verme L, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Alimentary Pharmacology & Therapeutics 2006; 23: 1567-1574. http://dx.doi.org/10.1111/j.1365-2036.2006.02927.x
Marteau P, Le´mann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomized, double blind, placebo controlled GETAID trial. Inflammatory Bowel Disease 2006; 55: 842-847. http://dx.doi.org/10.1136/gut.2005.076604
Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, DeVos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflammatory Bowel Diseases 2007; 13: 135. http://dx.doi.org/10.1002/ibd.20063
Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis. American Journal of Gastroenterolgy 2009; 104: 437-443. http://dx.doi.org/10.1038/ajg.2008.118
Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2009; 7: 1202-1209. http://dx.doi.org/10.1016/j.cgh.2009.07.016
Tursi A, Brandimarte G, Papa A, et al. Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL # 3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study. The American Journal of Gastroenterology 2010; 105: 2218-2227. http://dx.doi.org/10.1038/ajg.2010.218
Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complementary and Alternative Medicine 2010; 10: 1-8. http://dx.doi.org/10.1186/1472-6882-10-13
Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomized clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Alimentary Pharmacology & Therapeutics 2012; 35: 327-334. http://dx.doi.org/10.1111/j.1365-2036.2011.04939.x
Hatakka K, Martio J, Korpela M, Herranen M, Poussa T, Laasanen T, Saxelin M, Vapaatalo H, Moilanen E, Korpela R. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study. Scandinavian Journal of Rheumatology 2003; 32: 211-215. http://dx.doi.org/10.1080/03009740310003695
Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complementary and Alternative Medicine 2010; 10: 1-7. http://dx.doi.org/10.1186/1472-6882-10-1
Pineda MA, Thompson SF, Summers K, Leon F, Pope J, Reid G. A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Medical Science Monitor 2011; 17: 347-354.
Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: A randomized controlled trial. American Academy of Allergy, Asthma & Immunology 2007; 119: 184-191. http://dx.doi.org/10.1016/j.jaci.2006.08.036
Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, Paerregaard A. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. Journal of Allergy Clinical Immunology 2003; 111: 389-395. http://dx.doi.org/10.1067/mai.2003.389
Martínez-Cañavate A, Sierra S, Lara-Villoslada F,Romero J, Maldonado J, Boza J, Xaus J, Olivares M. A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy. Pediatr Allergy Immunology 2009; 20: 592-600. http://dx.doi.org/10.1111/j.1399-3038.2008.00833.x
Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, Savilahti E. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. Journal of Allergy Clinical Immunology 2004; 114: 131-136. http://dx.doi.org/10.1016/j.jaci.2004.03.036
Roitt IM, Brostoff J, Male DK. Immunology. Gower Medical, London 1998.
Male D, Brostoff J, Roth DB, Roitt I. immunology. Elsevier, Missouri 2006.
Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M,Tomiyasu N, Suzuki A, Sata M. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clinical and Experimental Immunology 2005; 140: 417-426. http://dx.doi.org/10.1111/j.1365-2249.2005.02790.x
Goudy KS, Burkhardt BR, Wasserfall C, et al. Systemic over-expression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. The Journal of Immunology 2003; 171: 2270-2278. http://dx.doi.org/10.4049/jimmunol.171.5.2270
Ejtahed HS, Mohtadi-Nia J, Homayouni A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type2 diabetic patients. Journal of Nutrition 2012; 28: 539-543. http://dx.doi.org/10.1016/j.nut.2011.08.013
Butler DM, Anne-Marie Malfait A, Maini RN, Brennan FM, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. European Journal of Immunology 2008; 29: 2205-2212. http://dx.doi.org/10.1002/(SICI)1521-4141(199907)29:07<2205::AID-IMMU2205>3.0.CO;2-Z
van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFa and IL18 but not CXCL12. Annals of the Rheumatic Diseases 2005; 64: 537-543. http://dx.doi.org/10.1136/ard.2004.024927
Milstein O, Hagin D, Lask A, et al. CTLs respond with activation and granule secretion when serving as targets for T-cell recognition. The American Society of Hematology 2011; 117: 1042-1052. http://dx.doi.org/10.1182/blood-2010-05-283770
Kay AB. Overview of 'allergy and allergic diseases: with a view to the future. British Medical Bulletin 2000; 56: 843-864. http://dx.doi.org/10.1258/0007142001903481
Janeway C, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. Garland Pub, London 2004.
Dugas B, Mercenier A, Lenoir-Wijnkoop I, Arnaud C, Dugas N, Postaire E. Immunity and probiotics. Immunology Today 1999; 20: 387-390. http://dx.doi.org/10.1016/S0167-5699(99)01448-6
Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. Journal of Allergy Clinical Immunology 1997; 99: 179-185. http://dx.doi.org/10.1016/S0091-6749(97)70093-9
Murch SH. Toll of allergy reduced by probiotics. Lancet 2001; 357: 1057-1059. http://dx.doi.org/10.1016/S0140-6736(00)04305-1
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2016 Parvin Bastani, Aziz Homayouni, Leila Norouzi-Panahi, Arash Tondhoush, Sharareh Norouzi, ElnazVaghef Mehrabany , Zahra Kasaie